Cancer evolution detection and diagnostic methods
Summary
The USPTO granted patent US12597524B2 to Guardant Health, Inc. covering methods for determining probability that a cancer patient's initial mutational state will develop a subsequent state after therapeutic interventions. The patent enables healthcare providers to select treatment courses that maximize probability of desired patient outcomes.
What changed
USPTO issued patent grant US12597524B2 to Guardant Health for cancer evolution detection and diagnostic methods. The patent covers computational methods for analyzing somatic cell mutational status and predicting progression probabilities following therapeutic interventions. The 20 granted claims span multiple CPC classifications including G16H (health informatics), G16B (bioinformatics), and C12Q (molecular biology assays).
Affected parties include diagnostic device manufacturers, pharmaceutical companies developing companion diagnostics, and healthcare providers implementing precision medicine protocols. Companies developing liquid biopsy assays, circulating tumor DNA analysis tools, or therapeutic response monitoring systems should evaluate whether their technologies fall within the scope of these claims. The patent strengthens Guardant Health's intellectual property position in the cancer diagnostics and therapeutic decision-support market.
What to do next
- Monitor patent landscape for potential licensing requirements
- Review diagnostic development programs for freedom-to-operate considerations
- Track related patent filings in cancer evolution detection space
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cancer evolution detection and diagnostic
Grant US12597524B2 Kind: B2 Apr 07, 2026
Assignee
Guardant Health, Inc.
Inventors
Helmy Eltoukhy, AmirAli Talasaz
Abstract
The present disclosure provides methods for determining a probability that after any of a number of therapeutic interventions, an initial state of a subject, such as somatic cell mutational status of a subject with cancer, will develop a subsequent state. Such probabilities can be used to inform a health care provider as to particular courses of treatment to maximize probability of a desired outcome for the subject.
CPC Classifications
G16H 50/30 G16H 50/20 G16B 20/20 G16B 40/00 G16B 20/00 G16B 20/10 C12Q 1/6886
Filing Date
2024-04-22
Application No.
18642389
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Health Informatics (G16H)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Health Informatics (G16H) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.